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Abstract
Unusual site deep vein thrombosis (USDVT) is an uncommon form of venous thromboembolism with heterogeneous signs and
symptoms, unknown rate of pulmonary embolism (PE), and poorly defined risk factors. We conducted a retrospective analysis of
107 consecutive cases of USDVTs, discharged from our University Hospital over a period of 2 years. Patients were classified based
on the site of thrombosis and distinguished between patients with cerebral vein thrombosis, jugular vein thrombosis, thrombosis
of the deep veins of the upper extremities, and abdominal vein thrombosis. We found statistically significant differences between
groups in terms of age (P < .0001) and gender distribution (P < .05). We also found that the rate of symptomatic patients was
significantly different between groups (P < .0001). Another interesting finding was the significant difference between groups in
terms of rate of PE (P < .01). Finally, we found statistically significant differences between groups in terms of risk factors for
thrombosis, in particular cancer (P < .01). Unprovoked cases were differently distributed among groups (P < .0001). This study
highlights differences between patients with USDVT, which depend on the site of thrombosis, and provides data which might be
useful in clinical practice.
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Introduction
Venous thromboembolism (VTE), including deep vein throm-
bosis (DVT) and pulmonary embolism (PE), affects 1 to 3 per
1000 persons per year in Western countries and represents the
third leading cause of cardiovascular mortality and the main
cause of preventable mortality among hospitalized patients in
the world.1-4
Although its most common clinical presentation involves
the deep veins of the lower limbs, DVT may potentially occur
in any section of the venous system. Indeed, DVT is also diag-
nosed, among others, in the veins of the arms, the jugular veins,
the cerebral venous system, the abdominal veins.5 The term
“unusual site deep vein thrombosis” (USDVT) is used to refer
to DVTs occurring in these relatively uncommon sites. Unusual
site deep vein thrombosis represents a clinical challenge
because of the heterogeneity of signs and symptoms, the poten-
tial severity of the clinical outcomes, and the lack of adequate
evidence from clinical trials in terms of treatment strategies.
Also, USDVTs have risk factors that may be different from
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those associated with DVT in canonical sites and are often
specific of the anatomical site where the thrombosis occurs.
In this study, we have retrospectively analyzed cases of
patients with cerebral vein thrombosis (CVT), jugular vein
thrombosis (JVT), thrombosis of the deep veins of the upper
extremities (UEDVT), and abdominal vein thrombosis (AVT),
in order to detect differences between groups, in terms of age,
gender, clinical features, rate of PE, risk factors for thrombosis,
and treatment.
Methods
Ethical Approval
The study was approved by the Ethics Committee of the Fon-
dazione Policlinico Universitario A. Gemelli IRCCS (Protocol
number 49904/18).
Identification and Characterization of Patients
With USDVT
We used the electronic database of the “Fondazione Policlinico
Universitario A. Gemelli IRCCS,” a University Hospital in
Rome, Italy. The search included the period between January
01, 2015, and December 31, 2016. The International Classifi-
cation of Diseases, Ninth Revision codes were used to identify
consecutive patients discharged with a diagnosis of VTE. Next,
the clinical charts of all identified patients were reviewed by 2
investigators, in order to confirm the diagnosis of DVT and
distinguish between DVT of the lower limbs (which were con-
sidered DVT in usual sites) and DVT occurring in other anato-
mical sites (which were considered USDVT). Cases of isolated
PE, without evidence of DVT, were excluded. For each patient
with USDVT, the following parameters were determined by 2
investigators: age at onset of DVT, gender, signs and symptoms
at hospital admission, concomitant presence of PE, risk factors
for thrombosis (as recorded by anamnesis or assessed by
laboratory and/or radiological examinations during hospital
stay), and treatment during hospitalization and at discharge
from the hospital.
Statistical Analyses
Comparisons were performed between patients with USDVT in
different anatomical sites. Variables were age, gender, rate of
symptomatic patients, rate of PE, and presence of risk factors.
Differences between groups were analyzed by one-way analy-
sis of variance for continuous variables and by bicategorical w2
for categorical variables. Differences were considered signifi-
cant for P < .05.
Results
The search of our database led to the identification of 744
patients discharged with a diagnosis of VTE. Of these, 107
were consecutive cases of USDVT. They consisted of 25 cases
of CVT, 16 cases of JVT, 33 cases of UEDVT, and 33 cases of
AVT. In all cases, CVT was diagnosed by either contrast-
enhance computed tomography (CT) scan and/or magnetic
resonance angiography of the brain. All the diagnoses of
UEDVT were done by upper extremities venous ultrasound
(US) and/or contrast-enhanced CT scan. All cases of JVT were
diagnosed by either US and/or contrast-enhanced CT scan of
the neck. All cases of AVTwere diagnosed by either abdominal
US and/or abdominal contrast-enhanced CT scan.
Age and Gender
All USDVTs were new diagnoses, thus age at onset corre-
sponded in all cases to age at the time of hospital admission.
The mean age in the CVT group was 47.1+ 15.0 years, while
in the JVT, UEDVT, and AVT groups was 60.0+ 21.6, 56.0
+ 17.5, and 55.5+ 15.8 years, respectively. Age differences
between groups were statistically significant (P < .0001). The
female sex was more frequent among patients with CVT
(72.0%), while the male sex was more common in the group
of patients with AVT (67.0%). Men represented the 50.0% and
the 48.4% of the patients in the JVT and UEDVT groups,
respectively. Differences in gender distribution were statisti-
cally significant between groups (P < .05). None of the female
patients was pregnant or in the postpartum period. These results
are presented in Table 1.
Clinical Presentation and Rate of PE
Of the 107 patients with USDVT, 80 (74.7%) presented at least
one sign or symptom of thrombosis at hospital admission.
However, the percentage of symptomatic patients was signifi-
cantly different among patients with CVT, JVT, UEDVT, and
Table 1. Baseline Characteristics and Clinical Presentation According to Thrombosis Site.
Characteristics CVT, n ¼ 25 JVT, n ¼ 16 UEDVT, n ¼ 33 AVT, n ¼ 33 P
Age, years+ SD 47.1+ 15.0 60 + 21.6 56 + 17.5 55.5+ 15.8 <.0001
Men, n (%) 7 (28.0%) 8 (50.0%) 16 (48.4%) 22 (66.6%) <.05
Symptomatic, n (%) 25 (100.0%) 12 (75.0%) 28 (84.8%) 15 (45.4%) <.0001
Concomitant PE
n/screened patients (%) 0/12 (0.0%) 0/12 (0.0%) 6/8 (75.0%) 9/28 (32.1%) <.001
n/whole cohort 0/25 (0.0%) 0/16 (0.0%) 6/33 (18.2%) 9/33 (27.3%) <.01
Abbreviations: AVT, abdominal vein thrombosis; CVT, cerebral vein thrombosis; JVT, jugular vein thrombosis; PE, pulmonary embolism; SD, standard deviation;
UEDVT, upper extremities deep vein thrombosis.
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AVT, as shown in Table 1 (P < .0001). In particular, the per-
centage of symptomatic patients was 100.0% in the CVT
group, 75.0% in the JVT group, 84.8% in the UEDVT group,
and 45.4% in the AVT group.
A total of 60 patients underwent CT scan of the chest (56.0%
of the total population). In detail, they were 12 patients with
CVT (on a total of 25), 8 patients with UEDVT (on a total of
33), 12 patients with JVT (on a total of 16), and 28 patients with
AVT (on a total of 33). One reason that led to the execution of
these CT scans was the presence of dyspnea. These patients
underwent CT pulmonary angiography to rule out or confirm a
suspicion of PE. Other reasons that, in the absence of dyspnea,
led to execution of CT scans of the chest were a suspicion of
cancer, or a known cancer that needed to be (re)staged. These
patients underwent contrast-enhanced CT scan of the chest as
part of a total body CT scan. Pulmonary embolism was rela-
tively frequent among patients with UEDVT: 75.0% of the
patients with UEDVT who underwent CT scan of the chest and
18.2% of the whole UEDVT population. Pulmonary embolism
was frequent also among patients with AVT: 32.1% of the
patients with AVT who underwent CT scan of the chest and
27.3% of the whole AVT cohort. On the other hand, no PE was
detected in the CVT and JVT groups, although a total of 20
patients underwent CT scan of the chest in these 2 cohorts.
Differences between groups were statistically significant
(P < .001 among patients screened for PE and P < .01 among
patients in the whole population). These results are reported
in Table 1.
Signs and symptoms at admission, distinguished according
to the thrombosis site, are presented in Table 2. Among
patients with CVT, headache was the most common symptom
(72.0%). Other frequent clinical manifestations of CVT were
focal neurologic deficits (28.0%), seizures (24.0%), nausea
and vomiting (24.0%), and aphasia (20.0%). Dyspnea was
never present (0.0%).
The most frequent signs and symptoms among patients with
JVT were pain and edema of the upper arm (25.0% and 25.0%,
respectively), neck swelling (12.5%), headache (12.5%), and
loss of consciousness (12.5%). Dyspnea was never present
(0.0%). Edema of the arm (66.6%) and pain of the arm
(39.4%) were the most common sign and symptom of
UEDVTs. In this cohort, dyspnea was relatively common (5
patients, 15.1%). Of these 5 patients with dyspnea, 4 had PE
and 1 did not have PE.
The symptoms found among patients with AVT were
abdominal pain (33.3%) and dyspnea (12.1%). In particular,
there were 4 patients with dyspnea. Of these, 3 had PE and 1
did not have PE.
Risk Factors for Thrombosis
The results of the analysis of risk factors for thrombosis are
presented in Table 3.
Cancer. Cancer was the most common risk factor in the whole
population. Indeed, 47 patients had cancer on a total of 107
individuals with USDVT (43.9%). Nonetheless, the frequency
of cancer was significantly different between the various types
of USDVT (P < .01). In particular, cancer was extremely fre-
quent among patients with AVT (75.7%) and JVT (56.2%). It
was less common among patients with CVT and UEDVT
(24.0% and 21.2%, respectively). Solid cancers constituted
76.6% of all neoplasms (36/47). Among hematological cancers
(n ¼ 11), 7 (63.6%) were JAK2-positive myeloproliferative
neoplasms (MPN). Of these, 3 were patients with CVT and 4
were patients with AVT.
Estrogen-containing oral contraceptives. A relevant percentage
(27.7%) of female patients with CVT was taking estrogen-
containing oral contraceptives. Of note, none of these women
had additional risk factors (in particular they did not have
cancer). The use of estrogen-containing oral contraceptives
was instead never found among women with JVT, UEDVT,
and AVT (36 women in total).
Other risk factors. The analysis of our database led to the iden-
tification of a number of risk factors and/or predisposing con-
ditions for thrombosis, which were heterogeneously distributed
among the various types of USDVT. For instance, the
Table 2. Signs and Symptoms According to Thrombosis Site.
Signs and symptoms in CVT patients, n ¼ 25
Headache, n (%) 18 (72.0%)
Focal neurologic deficits, n (%) 7 (28.0%)
Seizures, n (%) 6 (24.0%)
Nausea and vomiting, n (%) 6 (24.0%)
Aphasia, n (%) 5 (20.0%)
Loss of consciousness, n (%) 3 (12.0%)
Diplopia, n (%) 1 (4.0%)
Dizziness, n (%) 1 (4.0%)
Dyspnea, n (%) 0 (0.0%)
Signs and symptoms in JVT patients, n ¼ 16
Pain of the upper arm, n (%) 4 (25.0%)
Edema of the upper arm, n (%) 4 (25.0%)
Neck swelling, n (%) 2 (12.5%)
Headache, n (%) 2 (12.5%)
Loss of consciousness, n (%) 2 (12.5%)
Superior vena cava syndrome, n (%) 1 (6.2%)
Seizures, n (%) 1 (6.2%)
Dyspnea, n (%) 0 (0.0%)
Signs and symptoms in UEDVT patients, n ¼ 33
Edema of upper arm, n (%) 22 (66.6%)
Pain of the upper arm, n (%) 13 (39.4%)
Dyspnea, n (%) 5 (15.1%)
With PE, n (%) 4 (12.1%)
Without PE, n (%) 1 (3.0%)
Signs and symptoms in AVT patients, n ¼ 33
Abdominal pain, n (%) 11 (33.3%)
Dyspnea 4 (12.1%)
With PE, n (%) 3 (9.0%)
Without PE, n (%) 1 (3.0%)
Abbreviations: AVT, abdominal vein thrombosis; CVT, cerebral vein thrombo-
sis; JVT, jugular vein thrombosis; PE, pulmonary embolism; UEDVT, upper
extremities deep vein thrombosis.
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conditions most frequently associated with UEDVT were the
presence of a central venous catheter (CVC), the presence of a
pacemaker, and a diagnosis of thoracic outlet syndrome
(48.4%, 1.8%, and 18.1%, respectively). Liver cirrhosis (with
no cancer) was relatively frequent among patients with AVT
(15.1%). Other less frequent conditions associated with various
types of USDVT were sepsis, trauma, surgery, disseminated
intravascular coagulation, and pancreatitis.
Unprovoked Cases
There were a total of 20 patients (18.7% of the whole popula-
tion) who did not display any of the risk factors listed above.
The percentage of such unprovoked cases was 52.0% among
patients with CVT, 31.2% among patients with JVT, 6.1%
among patients with UEDVT, and 0.0% among patients
with AVT. These differences were statistically significant
(P < .0001; Table 3).
Review of clinical charts demonstrated that in all these
patients, a search for the following thrombophilic conditions
was performed: protein C deficiency, protein S deficiency,
Factor V Leiden (FV Leiden), G20210A prothrombin muta-
tion, antithrombin deficiency, lupus anticoagulant (LAC), and
antiphospholipid syndrome, elevated levels of Factor VIII
(FVIII). The results of thrombophilia screening in this popula-
tion are presented in Table 4. Among the 13 patients with
unprovoked CVT, we identified 1 case of protein C deficiency,
1 case of protein S deficiency, and 1 case of heterozygous FV
Leiden. One case of protein C deficiency was also identified
among the 5 patients with unprovoked JVT, while the search
for thrombophilia was negative in the 2 patients with unpro-
voked UEDVT. We also found 5 patients with a positive LAC
test (4 in the CVT group and 1 in the JVT group). However, in
none of these cases, LAC positivity was associated with the
presence of antibodies against cardiolipin and/or b2
glycoprotein-1. In addition, in none of these cases, we could
access medical data after hospital discharge to determine
whether LAC positivity was confirmed 3 months later. This
is an important limitation that significantly affects the interpre-
tation of LAC positivity in our cohort. Finally, there were 4
patients in the CVT group who displayed elevated levels of
FVIII (above the normal range of our hospital laboratory:
70%-140%). However, also in this case, we only had access
to the medical records of the period of hospitalization, thus the
elevated values that we report are those assessed at the time of
acute thrombosis. This is a limitation, since FVIII may be
transiently elevated in the acute inflammation phase response
to thrombosis. Therefore, its role as possible thrombophilic
condition in these patients remains uncertain.
We found that thrombophilia screening was performed also
in 18 cases with provoked thrombosis. The reason why these
patients were screened for thrombophilia was not always
Table 4. Thrombophilic Tests Among Patients With Unprovoked
Thrombosis.
Test
CVT,
n ¼ 13
JVT,
n ¼ 5
UEDVT,
n ¼ 2
Protein C deficiency, n (%) 1 (7.1%) 1 (20.0%) 0 (0.0%)
Protein S deficiency, n (%) 1 (7.1%) 0 (0.0%) 0 (0.0%)
Factor V Leiden (heterozygous), n (%) 1 (7.1%) 0 (0.0%) 0 (0.0%)
Factor V Leiden (homozygous), n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
G20210 A prothrombin mutation,
n (%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
Antithrombin deficiency, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Lupus anticoagulant, n (%), (only one
determination during hospitalization)
4 (28.5%) 1 (20.0%) 0 (0.0%)
Anti-cardiolipin antibodies, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Anti-b2 glycoprotein-1 antibodies,
n (%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
Elevated factor VIII, n (%), (only one
determination during hospitalization)
4 (28.5%) 0 (0.0%) 0 (0.0%)
Table 3. Risk Factors According to Thrombosis Site.
Risk Factor CVT, n ¼ 25 JVT, n ¼ 16 UEDVT, n ¼ 33 AVT, n ¼ 33 P
Cancer, n (%) 6 (24.0%) 9 (56.2%) 7 (21.2%) 25 (75.7%) <.01
Solid cancer, n (%) 3 (12.0%) 8 (50.0%) 6 (18.2%) 19 (57.6%)
Hematological cancer, n (%) 3 (12.0%) 1 (6.2%) 1 (3.0%) 6 (18.1%)
JAK2þ MPN, n (%) 3 (12.0%) 0 (0.0%) 0 (0.0%) 4 (12.1%)
Oral contraceptives, n/number of women (%) 5/18 (27.7%) 0/8, (0.0%) 0/17, (0.0%) 0/11, (0.0%)
CVC, n (%) 0 (0.0%) 0 (0.0%) 16 (48.4%) 0 (0.0%)
PM, n (%) 0 (0.0%) 0 (0.0%) 2 (1.8%) 0 (0.0%)
Thoracic outlet syndrome, n (%) 0 (0.0%) 0 (0.0%) 6 (18.1%) 0 (0.0%)
Liver cirrhosis, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (15.1%)
Trauma, n (%) 0 (0.0%) 1 (6.2%) 0 (0.0%) 0 (0.0%)
Sepsis, n (%) 0 (0.0%) 1 (6.2%) 0 (0.0%) 0 (0.0%)
DIC, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (3.0%)
Pancreatitis, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (3.0%)
Surgery, n (%) 1 (4.0%) 0 (0.0%) 0 (0.0%) 1 (3.0%)
None of the above-listed risk factors 13 (52.0%) 5 (31.2%) 2 (6.1%) 0 (0.0%) <.0001
Abbreviations: AVT, abdominal vein thrombosis; CVC, central venous catheter; CVT, cerebral vein thrombosis; DIC, disseminated intravascular coagulation;
JVT, jugular vein thrombosis; MPN, myeloproliferative neoplasm; PM, pacemaker; UEDVT, upper extremities deep vein thrombosis.
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clearly evident from the review of medical records, but in many
cases, it was because the screening was ordered before the
provoking factor for thrombosis was identified (as in cases of
new cancer diagnosis).
According to our database, screening for paroxysmal noc-
turnal hemoglobinuria (PNH) was performed in 4 patients. No
cases of PNH were found.
Treatment
We searched the database of our hospital to determine which
anticoagulant treatment was prescribed to patients with
USDVT during hospitalization and at the time of hospital dis-
charge. The results are presented in Table 5.
During hospital stay, 82 patients (16 with CVT, 11 with
JVT, 27 with UEDVT, and 28 with AVT) were treated
with low-molecular-weight heparins (LMWH), while 9
patients (5 with CVT, 2 with JVT, 1 with UEDVT, and
1 with AVT) were treated with unfractionated heparin.
There were 16 patients (4 with CVT, 3 JVT, 5 UEDVT,
and 4 with AVT) who did not receive anticoagulant ther-
apy while in the hospital.
At discharge from the hospital, 80 patients (14 with CVT,
14 with JVT, 26 with UEDVT, and 25 with AVT) were pre-
scribed LMWH, while 20 patients (9 with CVT, 1 with JVT, 4
with UEDVT, and 6 with AVT) received prescription of an
oral anticoagulant. According to the medical records, there
were 7 patients (2 with CVT, 1 with JVT, 3 with UEDVT,
and 2 with AVT) who did not receive any antithrombotic
prescription upon discharge. Among patients discharged with
oral anticoagulants, 13 (8 with CVT, 1 with JVT, 1 with
UEDVT, and 3 AVT) received a vitamin K antagonist and 7
(1 with CVT, 3 with UEDVT, and 3 AVT) received a direct
oral anticoagulant (DOAC). Among patients treated with
DOAC, 3 received dabigatran, 3 received rivaroxaban, and
1 received apixaban.
Discussion
This is retrospective analysis of 107 consecutive cases of
USDVT, with a focus on the demographic characteristics, clin-
ical features, risk factors, and treatment, according to the
thrombosis site.
Our results indicate that patients affected by CVT are more
frequently young women, while patients with AVT are more
commonly men. This is consistent with previous reports in the
literature.6-9 Second, it suggests that all cases of CVTs are
symptomatic, while DVTs in other unusual sites may often be
asymptomatic. Regarding PE, it is interesting to observe that
its rate is 0.0% in our series of patients with CVT and JVT,
while it is relatively common in the groups of patients with
AVT. Pulmonary embolism is also frequent among patients
with UEDVT, consistent with the results of a previous study
that showed the presence of PE in 10% to 25% of patients with
UEDVT.10
The analysis of risk factors revealed that cancer is largely
the most common pathological condition associated with
USDVT, especially AVT and JVT, consistent with other series
in the literature.11 Solid cancers are more common than hema-
tological cancers. Nonetheless, hematological cancers—and
especially JAK2-positive MPN—have a relevant role in
patients with CVT and AVT in our population. Among women
with CVT, in addition to cancer, a common risk factor is the use
of estrogen-containing oral contraceptives. This finding is
consistent with previously published data.9 A significant risk
factor for JVT reported in the literature is the presence of a
CVC.12 However, none of our patients had CVC-related
thrombosis of the jugular vein. In our study, the presence of
a CVC is instead the main risk factor for UEDVT. When these
cases are added to those with thrombosis associated with an
implantable cardiac device, they account for more than 50%
of all UEDVTs. Thus, these patients need to be distinguished
by those with thrombosis not associated with a device. In the
latter case, cancer is again the most frequent risk factor. These
findings are consistent with the results of a recent study that
has reported that about 70% of UEDVTs are CVC-related and
30% to 40% occur in patients with cancer, with the risk of
UEDVT being almost doubled in patients with an active can-
cer that also carry a CVC.13
An interesting finding of this study is the significantly dif-
ferent number of unprovoked thromboses between patients
with CVT, JVT, UEDVT, and AVT. In particular, more than
half of patients with CVT did not display any convincing risk
factor for thrombosis. On the contrary, there were no case of
unprovoked thrombosis among patients with AVT. According
to our analysis, hereditary coagulopathies and thrombophilic
conditions may explain only a portion of these unprovoked
USDVT. Indeed, we only found 2 cases of protein C and pro-
tein S deficiency in the group of unprovoked CVT and 1 case of
protein C deficiency in the group of unprovoked JVT. In addi-
tion to that, there was 1 patient with heterozygous FV Leiden in
the CVT group. Regarding LAC positivity that was found dur-
ing hospitalization in 4 cases of unprovoked CVT and 1 case of
Table 5. Treatment During Hospitalization and at Discharge
According to Thrombosis Site.
Treatment
CVT,
n ¼ 25
JVT,
n ¼ 16
UEDVT,
n ¼ 33
AVT,
n ¼ 33
During hospitalization
LMWH, n (%) 16 (64.0%) 11 (68.8%) 27 (81.8%) 28 (84.8%)
UFH, n (%) 5 (20.0%) 2 (12.5%) 1 (3.0%) 1 (3.0%)
No treatment,
n (%)
4 (16.0%) 3 (18.8%) 5 (15.6%) 4 (12.1%)
At discharge
LMWH, n (%) 14 (56.0%) 14 (87.5%) 26 (78.8%) 25 (75.8%)
AVK, n (%) 8 (32.0%) 1 (6.2%) 1 (3.0%) 3 (9.1%)
DOAC, n (%) 1 (4.0%) 0 (0.0%) 3 (9.1%) 3 (9.1%)
No treatment,
n (%)
2 (8.0%) 1 (6.2%) 3 (9.1%) 2 (6.1%)
Abbreviations: AVK, antivitamin K; AVT, abdominal vein thrombosis; CVT,
cerebral vein thrombosis; DOAC, direct oral anticoagulants; JVT, jugular vein
thrombosis; LMWH, low-molecular-weight heparin; UEDVT, upper extremi-
ties deep vein thrombosis; UFH, unfractionated heparin.
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unprovoked JVT, it is important to mention that we could not
evaluate whether it was confirmed 3 months after the first
determination, therefore its actual role in the pathogenesis of
these thromboses remains uncertain. Similarly, there were 4
patients with elevated levels of FVIII during the acute phase
of unprovoked CVT, but it is unknown whether these data were
confirmed at later time points, making impossible to establish
whether high FVIII was a transient phenomenon or an actual
prothrombotic condition.
Regarding treatment, most patients were treated with
LMWH during hospitalization. Low-molecular-weight hepar-
ins were the most prescribed anticoagulant drugs at the moment
of hospital discharge as well. It is interesting to note that only a
small portion of patients were discharged from the hospital
with the prescription of an oral anticoagulant (20 on a total
of 107 patients). This might depend on the fact that the vast
majority of patients were affected by cancer, and LMWH still
represents the first treatment option for cancer-associated VTE.
We also found 7 patients who were discharged from the hos-
pital with DOAC prescription. This indicates that DOACs are
being used in clinical practice for the treatment of USDVTs,
although convincing evidence on efficacy and safety of these
medications in patients with thromboses in unusual sites are
still lacking.
This study has some limitations. It is a retrospective analysis
of medical records and data might be missing, especially
regarding risk factors for thrombosis. Therefore, it is possible
that the actual number of unprovoked cases might be lower
than observed. Another limitation, as mentioned above, is the
fact that some possible thrombophilic conditions, such as LAC
positivity, elevated levels of FVIII, and PNH, were not fully
investigated. Regarding the relatively small sample size, this
might be a limitation, although it is worth mentioning that our
cohort of 107 patients with USDVT is comparable with the
most recent series available in the literature.6 Finally, even if
USDVTs are relatively rare, in our study, they accounted for
more than 14% of all cases of VTE discharged from our hos-
pital over a 2-year period. This high percentage might be due to
the fact that our study only focused on inpatients, while many
DVTs in usual site are often managed in an outpatient setting.
Conclusion
In conclusion, this study highlights demographical, epide-
miological, clinical, and therapeutic differences between
patients with USDVT, which mainly depend on the site of
thrombosis, and provides potentially useful information for
correct identification and management of patients with
USDVTs in clinical practice.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, author-
ship, and/or publication of this article.
ORCID iD
Angelo Porfidia https://orcid.org/0000-0003-4915-2892
Roberto Pola https://orcid.org/0000-0001-5224-2931
References
1. White RH. The epidemiology of venous thromboembolism.
Circulation. 2003;107(23 suppl 1):I4-I8.
2. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboem-
bolism (VTE) in Europe. The number of VTE events and associ-
ated morbidity and mortality. Thromb Haemost. 2007;98(4):
756-764.
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-
based perspective of the hospital incidence and case-fatality rates
of deep vein thrombosis and pulmonary embolism. TheWorcester
DVT study. Arch Intern Med. 1991;151(5):933-938.
4. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM,
Melton LJ III. Trends in the incidence of deep vein thrombosis
and pulmonary embolism: a 25-year population-based study. Arch
Intern Med. 1998;158(6):585-593.
5. Martinelli I. Unusual forms of venous thrombosis and thrombo-
philia. Pathophysiol Haemost Thromb. 2002;32(5-6):343-345.
6. Koonarat A, Rattarittamrong E, Tantiworawit A, et al. Clinical
characteristics, risk factors, and outcomes of usual and unusual
site venous thromboembolism. Blood Coagul Fibrinolysis. 2018;
29:12-18.
7. Porfidia A, Carnicelli A, Bonadia N, Pola R, Landolfi R. Con-
troversies in venous thromboembolism: the unique case of iso-
lated distal deep vein thrombosis. Intern Emerg Med. 2016;11(6):
775-779.
8. Di Nisio M, Carrier M. Incidental venous thromboembolism: is
anticoagulation indicated? Hematology Am Soc Hematol Educ
Program. 2017;2017(1):121-127.
9. Martinelli I. Cerebral vein thrombosis. Thromb Res. 2013;
131(suppl 1):S51-S54.
10. Kleinjan A, Di Nisio M, Beyer-Westendorf J, et al. Safety and
feasibility of a diagnostic algorithm combining clinical probabil-
ity, D-dimer testing, and ultrasonography for suspected upper
extremity deep venous thrombosis: a prospective management
study. Ann Intern Med. 2014;160(7):451-457.
11. Gbaguidi X, Janvresse A, Benichou J, Cailleux N, Levesque H,
Marie I. Internal jugular vein thrombosis: outcome and risk fac-
tors. QJM. 2011;104(3):209-219.
12. Karnik R, Valentin A, Winkler WB, Donath P, Slany J. Duplex
sonographic detection of internal jugular venous thrombosis after
removal of central venous catheters. Clin Cardiol. 1993;16(1):
26-29.
13. Kraaijpoel N, Van Es N, Porreca E, Bu¨ller HR, Di Nisio M.The
diagnostic management of upper extremity deep vein thrombosis:
a review of the literature. Thromb Res. 2017;156:54-59.
6 Clinical and Applied Thrombosis/Hemostasis
